202 related articles for article (PubMed ID: 16532916)
1. Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin-induced dysmenorrhea.
Liedman R; Grant L; Igidbashian S; James I; McLeod A; Skillern L; Akerlund M
Acta Obstet Gynecol Scand; 2006; 85(2):207-11. PubMed ID: 16532916
[TBL] [Abstract][Full Text] [Related]
2. Effects of a vasopressin antagonist in women with dysmenorrhea.
Valentin L; Sladkevicius P; Kindahl H; Broeders A; Marsal K; Melin P
Gynecol Obstet Invest; 2000; 50(3):170-7. PubMed ID: 11014949
[TBL] [Abstract][Full Text] [Related]
3. Validation of a test model of induced dysmenorrhea.
Liedman R; Skillern L; James I; McLeod A; Grant L; Akerlund M
Acta Obstet Gynecol Scand; 2006; 85(4):451-7. PubMed ID: 16612708
[TBL] [Abstract][Full Text] [Related]
4. Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin-induced uterine contractions.
Bossmar T; Brouard R; Döberl A; Akerlund M
Br J Obstet Gynaecol; 1997 Apr; 104(4):471-7. PubMed ID: 9141585
[TBL] [Abstract][Full Text] [Related]
5. Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea.
Akerlund M; Melin P; Maggi M
Adv Exp Med Biol; 1995; 395():595-600. PubMed ID: 8714023
[TBL] [Abstract][Full Text] [Related]
6. A randomized double blind comparison of atosiban in patients undergoing IVF treatment.
Ng EH; Li RH; Chen L; Lan VT; Tuong HM; Quan S
Hum Reprod; 2014 Dec; 29(12):2687-94. PubMed ID: 25336707
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women.
Steinwall M; Bossmar T; Gaud C; Akerlund M
Acta Obstet Gynecol Scand; 2004 Jan; 83(1):12-8. PubMed ID: 14678081
[TBL] [Abstract][Full Text] [Related]
8. Can primary dysmenorrhea be alleviated by a vasopressin antagonist? Results of a pilot study.
Akerlund M
Acta Obstet Gynecol Scand; 1987; 66(5):459-61. PubMed ID: 3321865
[TBL] [Abstract][Full Text] [Related]
9. Evidence for an involvement of vasopressin in mechanism of primary dysmenorrhea and effect of the non-peptide vasopressin V1a receptor antagonist, SR 49059, on the uterus of non-pregnant women.
Akerlund M; Bossmar T; Brouard R; Steinwall M
Adv Exp Med Biol; 1998; 449():467-72. PubMed ID: 10026840
[No Abstract] [Full Text] [Related]
10. Oxytocin and vasopressin constrict rat isolated uterine resistance arteries by activating vasopressin V1A receptors.
Chen YL; Shepherd C; Spinelli W; Lai FM
Eur J Pharmacol; 1999 Jul; 376(1-2):45-51. PubMed ID: 10440088
[TBL] [Abstract][Full Text] [Related]
11. Involvement of oxytocin and vasopressin in the pathophysiology of preterm labor and primary dysmenorrhea.
Akerlund M
Prog Brain Res; 2002; 139():359-65. PubMed ID: 12436949
[TBL] [Abstract][Full Text] [Related]
12. The oxytocin/vasopressin receptor antagonist atosiban delays the gastric emptying of a semisolid meal compared to saline in human.
Ohlsson B; Björgell O; Ekberg O; Darwiche G
BMC Gastroenterol; 2006 Mar; 6():11. PubMed ID: 16542457
[TBL] [Abstract][Full Text] [Related]
13. Treatment of preterm labor with the oxytocin and vasopressin antagonist Atosiban.
Bossmar T
J Perinat Med; 1998; 26(6):458-65. PubMed ID: 10224602
[TBL] [Abstract][Full Text] [Related]
14. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group.
Valenzuela GJ; Sanchez-Ramos L; Romero R; Silver HM; Koltun WD; Millar L; Hobbins J; Rayburn W; Shangold G; Wang J; Smith J; Creasy GW
Am J Obstet Gynecol; 2000 May; 182(5):1184-90. PubMed ID: 10819856
[TBL] [Abstract][Full Text] [Related]
15. Design of oxytocin antagonists, which are more selective than atosiban.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
[TBL] [Abstract][Full Text] [Related]
16. Barusiban suppresses oxytocin-induced preterm labour in non-human primates.
Reinheimer TM
BMC Pregnancy Childbirth; 2007 Jun; 7 Suppl 1(Suppl 1):S15. PubMed ID: 17570159
[TBL] [Abstract][Full Text] [Related]
17. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human.
Goodwin TM; Paul R; Silver H; Spellacy W; Parsons M; Chez R; Hayashi R; Valenzuela G; Creasy GW; Merriman R
Am J Obstet Gynecol; 1994 Feb; 170(2):474-8. PubMed ID: 8116700
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
[TBL] [Abstract][Full Text] [Related]
19. The oxytocin antagonist atosiban versus the beta-agonist terbutaline in the treatment of preterm labor. A randomized, double-blind, controlled study.
European Atosiban Study Group
Acta Obstet Gynecol Scand; 2001 May; 80(5):413-22. PubMed ID: 11328217
[TBL] [Abstract][Full Text] [Related]
20. Plasma concentrations of vasopressin and a prostaglandin F2 alpha metabolite in women with primary dysmenorrhoea before and during treatment with a combined oral contraceptive.
Hauksson A; Akerlund M; Forsling ML; Kindahl H
J Endocrinol; 1987 Nov; 115(2):355-61. PubMed ID: 3125302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
